BNT162b2: Clinical Trials

3 trials of BNT162b2, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 unknown. 3 Phase 1, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 13Completed 2, Unknown 1
Phase 23Completed 2, Unknown 1

Follow BNT162b2: new trials by email Literature Review of BNT162b2 trials Research Report on BNT162b2

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
The Immune Response of Heterologous Boost Third Dose of mRNA and Protein COVID-19 Vaccine
BNT162b2, mRNA-1273, MVC-COV1901 - COVID-19, Breakthrough Infection
Phase 1 / Phase 2UnknownChang Gung Memorial Hospital3402021-11-302022-07-25
Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines
Ad26.COV2.S, BNT162b2, mRNA-1273 - COVID-19
Phase 1 / Phase 2CompletedNational Institute of Allergy and Infectious Diseases (NIAID)8672021-05-282025-04-20
A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 in Healthy and Immunocompromised Adults
BNT162a1, BNT162b1, BNT162b2 - Infections, Respiratory, Virus Diseases
Phase 1 / Phase 2CompletedBioNTech SE5122020-04-232024-07-12

Conditions studied

COVID-19 (3)  ·  Breakthrough Infections (1)  ·  RNA Virus Infections (1)  ·  Respiratory Tract Infections (1)  ·  Severe Acute Respiratory Syndrome (1)  ·  Virus Diseases (1)

Sponsors

BioNTech SE (1)  ·  Chang Gung Memorial Hospital (1)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (1)

Countries

Germany (1)  ·  Taiwan (1)  ·  United States (1)

Top investigators

Cheng-Hsun Chiu, MD, PhD (1)  ·  Kirsten E Lyke, M.D. (1)  ·  Robert L Atmar, M.D. (1)

Results publications

PMID 35081293, PMID 35798000, PMID 36125366, PMID 36399969, PMID 37433788, PMID 37992183, PMID 39197299, PMID 40298376

NIH funding

5UM1AI148684-02 (1)